InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.84
(
-0.09%
)
Bitcoin
60,113.66
(
-0.07%
)
Post# of 252477
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 222593

Monday, 12/03/2018 2:28:15 PM

Monday, December 03, 2018 2:28:15 PM

Post# of 252477

the market absolutely hates this deal for GSK...

The reason is that the deal won't be accretive to GSK's EPS until 2022 at the earliest.

GSK essentially got out of oncology in 2014—just as the sector was heating up. So, now they may be overcompensating to some degree in getting back in.

Still, PARP inhibitors have a lot of upside, so I can’t say for sure that this deal is a mistake.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up